Market Intelligence, Clinical Progress, and High-Purity Reagents for Hedgehog Pathway Inhibitor Resistance Development.
SMO D473H Mutation and Resistance Mechanisms
The SMO D473H mutation (Asp473 to His) is a hotspot resistance alteration in the Smoothened receptor, primarily identified in patients with basal cell carcinoma and medulloblastoma. This mutation lies within the transmembrane domain and disrupts the binding pocket for first-generation inhibitors such as vismodegib and sonidegib, leading to constitutive activation of the Hedgehog signaling pathway. Key genomic references include dbSNP rs87 (associated with CRJS) and rs17710891, as well as somatic mutations found in basal cell carcinoma and ameloblastoma samples. Understanding these mutations is critical for developing next-generation inhibitors that can accommodate the altered pocket.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SMO D473H drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Mutant) | SMO D473H Mutant Recombinant Protein. High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed with native glycosylation. | View SMO D473H Products |
| Antigen (WT Control) | SMO Wild-Type Recombinant Protein. For selectivity screening. Theoretical MW verified. | View SMO Products |
| Gene Delivery | SMO D473H Lentivirus Premade Particles. Full-length ORF for stable cell line generation. Preserves native 7-TM membrane topology. | View SMO D473H Products |
| Benchmark Ab | Anti-SMO (Vismodegib Competition Epitope) Recombinant Rabbit mAb. Positive control for binding and expression assays. | View SMO Products |
| Validator | SMO siRNA Set. For knockdown verification and specificity controls in rescue experiments. | View SMO Products |
| Pathway Ligand | SHH (Sonic Hedgehog) Recombinant Protein. Activate signaling for functional assays. | View SHH Products |
| Upstream Regulator | PTCH1 Recombinant Protein. Hedgehog receptor for pathway studies and epistasis analysis. | View PTCH1 Products |
| Downstream Readout | GLI1 Recombinant Protein. Transcription factor for reporter assays and DNA-binding studies. | View GLI1 Products |
Critical Assay Challenges and TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Resistance Mutation Selectivity (D473H vs WT) | Matched Pair Proteins: Human SMO D473H mutant and SMO WT both available with >95% purity, Sequence Verified, enabling same-plate selectivity comparison. |
| GPCR Conformational Integrity | Lentivirus Particles for Stable Cell Lines: Preserve native glycosylation and 7-TM topology in mammalian membranes; avoid VLP artifacts. |
| Pathway-Specific Off-target Screening | Frizzled Homolog Panel (FZD4, FZD5) available for counter-screening against Class F GPCRs. |
| Lack of Reliable Controls | Clinical Benchmark Antibodies (biosimilars) and validated siRNA included for assay standardization and knockdown specificity. |
| False Positives in High-Throughput Screening | Validated siRNA enables endogenous SMO knockdown and phenotypic rescue confirmation. |
Live SMO D473H R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race to overcome SMO inhibitor resistance is intensifying. First-generation agents (vismodegib, sonidegib) transformed basal cell carcinoma care, but acquired mutations — most notably D473H — limit durable responses. The next wave of R&D focuses on next-generation small molecules capable of binding the mutant pocket, allosteric modulators that bypass the mutated residue, and targeted protein degraders (PROTACs) to eliminate the mutant receptor. Cell-based systems that present D473H in its native membrane context are now the standard for discriminating true mutant inhibitors from WT-restricted compounds. Major players include Genentech/Roche, Novartis, Pfizer, Vertex, and emerging biotechs exploring PROTACs and combination strategies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Next-Gen Small Molecule (Orthosteric) | Genentech/Roche, Novartis, Pfizer, PellePharm | Vismodegib-Resistant BCC, Medulloblastoma | Mutant vs WT Selectivity Assay (Need D473H and WT lentivirus stable cell lines or matched proteins) |
| Allosteric Inhibitors | Vertex, Curis, Emerging Biotech | Refractory Solid Tumors, AML | Conformation-Sensitive Binding Assay (Need full-length membrane-expressed SMO; lentivirus stable lines) |
| PROTACs / Targeted Degraders | Academic / Emerging Biotech | Medulloblastoma, Resistant BCC | Internalization/Degradation Assay (Need specific D473H stable cell lines with full-length ORF) |
| Combination Therapy (SMO + Chemo/GLI) | Genentech/Roche, Novartis | Pancreatic, BCC, Advanced Solid Tumors | Pathway Reporter Assay & Cross-talk validation (Need SHH, PTCH1, GLI1 high-purity reagents) |